State Street Corp Has $21.75 Million Holdings in Liquidia Co. (NASDAQ:LQDA)

State Street Corp lessened its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,175,378 shares of the company's stock after selling 56,301 shares during the period. State Street Corp owned approximately 2.83% of Liquidia worth $21,754,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Sapient Capital LLC bought a new position in Liquidia during the 3rd quarter worth about $1,336,000. BNP Paribas Financial Markets raised its stake in shares of Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock valued at $1,402,000 after purchasing an additional 123,402 shares during the period. HighVista Strategies LLC bought a new stake in shares of Liquidia in the second quarter valued at about $1,461,000. Finally, Acuta Capital Partners LLC bought a new position in shares of Liquidia during the third quarter worth about $735,000. 64.54% of the stock is owned by institutional investors.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 3,892 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the sale, the chief financial officer now owns 311,076 shares of the company's stock, valued at approximately $3,456,054.36. The trade was a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,260 shares of the firm's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock worth $245,780 over the last ninety days. Insiders own 30.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Lifesci Capital started coverage on Liquidia in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on Liquidia in a research report on Friday. They set an "overweight" rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $25.38.

Liquidia Trading Up 0.8 %

Shares of LQDA traded up $0.09 during mid-day trading on Tuesday, reaching $11.53. The company's stock had a trading volume of 341,019 shares, compared to its average volume of 967,983. The stock has a market cap of $975.86 million, a P/E ratio of -7.07 and a beta of 0.22. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $16.99. The business has a 50-day simple moving average of $10.92 and a two-hundred day simple moving average of $11.12.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).